文献速递肿瘤 PET/CT核素与放射性配体治疗

Al18F-NOTA-FAPI-74与18F-FDG PET/CT在肝胆恶性肿瘤评估与分期中的比较:单中心前瞻性研究

Comparison of Al 18 F-NOTA-FAPI-74 and 18 F-FDG PET/CT in the Evaluation and Staging of Hepatobiliary Malignancies : A Single-center Prospective Study.
PubMed 文献 · Clin Nucl Med · 2025-04-24

该单中心前瞻性研究纳入28例肝胆恶性肿瘤患者,配对行Al18F-NOTA-FAPI-74与18F-FDG PET/CT。Al18F-NOTA-FAPI-74 PET/CT在检测原发肿瘤、淋巴结转移及骨和内脏转移方面灵敏度均高于18F-FDG PET/CT,并使6/28例患者分期或再分期发生改变;FAPI摄取与FAP表达呈正相关(r=0.730,P=0.04)。

要点

  • Al18F-NOTA-FAPI-74 PET/CT检测原发肿瘤灵敏度100%(13/13),高于18F-FDG PET/CT的92.3%(12/13)。
  • Al18F-NOTA-FAPI-74 PET/CT检测淋巴结转移灵敏度79.2%(42/53),高于18F-FDG PET/CT的54.7%(29/53)。
  • Al18F-NOTA-FAPI-74 PET/CT检测骨和内脏转移灵敏度97.6%(164/168),高于18F-FDG PET/CT的69.0%(116/168)。

核心结论

  • 在肝胆恶性肿瘤患者中,Al18F-NOTA-FAPI-74 PET/CT在检测原发肿瘤和转移性病变方面优于18F-FDG PET/CT,使分期或再分期更准确。
  • Al18F-NOTA-FAPI-74 PET/CT对肿瘤相关梗阻性炎症检测效能好,该炎症仅见于胆管癌,因此Al18F-NOTA-FAPI-74有潜力鉴别肝内胆管癌与肝细胞癌。

研究设计与样本

  • 单中心前瞻性研究,于2023年4月至2024年3月前瞻性纳入肝胆恶性肿瘤参与者,配对行Al18F-NOTA-FAPI-74与18F-FDG PET/CT。
  • 以组织病理学和/或随访影像作为参考标准。
  • 采用Wilcoxon符号秩检验比较原发灶和转移灶的SUVmax,采用Spearman r相关分析Al18F-NOTA-FAPI-74摄取强度与免疫组化FAP表达的关系。
  • 队列共28例肝胆恶性肿瘤患者,包括12例肝细胞癌、13例肝内胆管癌、2例肝门部胆管癌和1例胆囊癌;其中13例初次分期、15例再分期。

主要发现

  • Al18F-NOTA-FAPI-74 PET/CT检测原发肿瘤灵敏度100%(13/13)vs 18F-FDG PET/CT 92.3%(12/13)。
  • Al18F-NOTA-FAPI-74 PET/CT检测淋巴结转移灵敏度79.2%(42/53)vs 18F-FDG PET/CT 54.7%(29/53)。
  • Al18F-NOTA-FAPI-74 PET/CT检测骨和内脏转移灵敏度97.6%(164/168)vs 18F-FDG PET/CT 69.0%(116/168)。
  • 与基于18F-FDG PET/CT的分期相比,Al18F-NOTA-FAPI-74 PET/CT使6/28例患者分期上调或再分期改变。
  • Al18F-NOTA-FAPI-74 PET/CT检测肿瘤相关梗阻性炎症7例,18F-FDG PET/CT仅检测1例(25% vs 3.6%);7例均为胆管癌(5例肝内胆管癌、2例肝门部胆管癌)。

临床怎么用

  • 原文结论未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Accurate diagnosis and staging are crucial for the management of patients with hepatobiliary malignancies. Here, we investigated the efficacy of Al 18 F-NOTA-FAPI-74 PET/CT in detecting hepatobiliary malignancies and compared the results with 18 F-FDG PET/CT. PATIENTS AND METHODS: Participants with hepatobiliary malignancies were prospectively enrolled and underwent paired Al 18 F-NOTA-FAPI-74 and 18 F-FDG PET/CT from April 2023 to March 2024. Histopathology and/or follow-up imaging served as the reference standard. The SUVmax of the primary and metastatic lesions between Al 18 F-NOTA-FAPI-74 and 18 F-FDG PET/CT were compared using the Wilcoxon signed-rank test. The association between Al 18 F-NOTA-FAPI-74 uptake intensity and immunohistochemical FAP expression was analyzed with Spearman r correlation. RESULTS: Our cohort comprised of 28 patients with hepatobiliary malignancies, including 12 with hepatocellular carcinoma, 13 with intrahepatic cholangiocarcinoma (ICC), 2 with perihilar cholangiocarcinoma, and 1 with gallbladder carcinoma. Of these 28 patients, 13 underwent PET/CT for initial staging and 15 for restaging. Al 18 F-NOTA-FAPI-74 PET/CT showed higher sensitivity than 18 F-FDG PET/CT for detecting primary tumors [100% (13/13) vs 92.3% (12/13)], lymph node metastases [79.2% (42/53) vs 54.7% (29/53)], and bone and visceral metastases [97.6% (164/168) vs 69.0% (116/168)]. Al 18 F-NOTA-FAPI-74 PET/CT findings led to upstaging or restaging in 6 of 28 patients compared with the 18 F-FDG PET/CT-based stage. In addition, Al 18 F-NOTA-FAPI-74 PET/CT detected tumor-related obstructive inflammation in 7 patients, while 18 F-FDG PET/CT detected it in only 1 patient (25% vs 3.6%). All these 7 patients suffered from cholangiocarcinomas, including 5 with ICC and 2 with perihilar cholangiocarcinomas. The SUVmax of obstructive inflammation on Al 18 F-NOTA-FAPI-74 PET/CT was significantly lower than that of tumor (median SUVmax, 4.0 vs 8.8; P = 0.008). A positive correlation was found between FAPI uptake and FAP expression ( r = 0.730, P = 0.04). CONCLUSIONS: In patients with hepatobiliary malignancies, Al 18 F-NOTA-FAPI-74 PET/CT outperformed 18 F-FDG PET/CT in detecting primary tumors and metastatic lesions, resulting in more accurate staging or restaging. In addition, Al 18 F-NOTA-FAPI-74 PET/CT showed good detection efficacy for tumor-related obstructive inflammation, which was only found in cholangiocarcinoma, thus rendering Al 18 F-NOTA-FAPI-74 the potential to differentiate ICC from hepatocellular carcinoma.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Hou G, Cheng X, Jiang Y, et al. Comparison of Al 18 F-NOTA-FAPI-74 and 18 F-FDG PET/CT in the Evaluation and Staging of Hepatobiliary Malignancies : A Single-center Prospective Study. Clin Nucl Med. 2025. PMID: 40279677. doi:10.1097/RLU.0000000000005889

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。